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Abstract
Over 150 mutations in the SCN2A gene, which encodes the neuronal Nav1.2 protein, have been implicated in
human epilepsy cases. Of these, R1882Q and R853Q are two of the most commonly reported mutations. This
study utilized voltage-clamp electrophysiology to characterize the biophysical effects of the R1882Q and R853Q
mutations on the hNav1.2 channel, including their effects on resurgent current and gating pore current, which are
not typically investigated in the study of Nav1.2 channel mutations. HEK cells transiently transfected with DNA
encoding either wild-type (WT) or mutant hNav1.2 revealed that the R1882Q mutation induced a gain-of-function
phenotype, including slowed fast inactivation, depolarization of the voltage dependence of inactivation, and
increased persistent current. In this model system, the R853Q mutation primarily produced loss-of-function
effects, including reduced transient current amplitude and density, hyperpolarization of the voltage dependence
of inactivation, and decreased persistent current. The presence of a Nav4 peptide (KKLITFILKKTREK-OH) in the
pipette solution induced resurgent currents, which were increased by the R1882Q mutation and decreased by
the R853Q mutation. Further study of the R853Q mutation in Xenopus oocytes indicated a reduced surface
expression and revealed a robust gating pore current at negative membrane potentials, a function absent in the
WT channel. This not only shows that different epileptogenic point mutations in hNav1.2 have distinct biophysical
effects on the channel, but also illustrates that individual mutations can have complex consequences that are
difficult to identify using conventional analyses. Distinct mutations may, therefore, require tailored pharmaco-
therapies in order to eliminate seizures.
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Significance Statement
This study expands our understanding of the pathogenic biophysical effects associated with two common
epilepsy mutations in the human neuronal voltage-gated sodium channel, hNav1.2. We show that different
point mutations in hNav1.2 that are implicated in epilepsy syndromes have distinct biophysical effects on
the channel, some of which are not revealed by standard electrophysiological analyses. The data herein
suggests that alterations in resurgent currents and/or the creation of a gating pore, which is distinct from
the central pore, may be involved in the mechanisms by which hNav1.2 mutations contribute to epilepsy and
other problems. Uncovering the distinct mechanisms by which different mutations contribute to aberrant
electrical activity will help us to develop more effective and personalized therapies for epileptic patients.
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Introduction
Over 150 mutations in the SCN2A gene, which encodes
the neuronal voltage-gated sodium channel Nav1.2, have
been implicated in human epilepsy cases, but few of them
have been studied in vitro to determine the molecular
basis of their pathogenicity. Many of these epilepsy cases
are refractory to current pharmacological interventions,
and understanding the molecular mechanisms by which
these mutations cause epileptiform activity in the brain
can help us find more effective pharmacological treat-
ments.
Mutations in SCN2A are thought to cause epileptic
seizures by allowing an excess of sodium to enter af-
fected neurons, causing the neurons to aberrantly fire
action potentials. This can be caused by shifts in gating
parameters (e.g., the voltage dependences of activation
and inactivation), altered channel conductance, altered
expression of the channels in the neuronal membrane, or
increases in auxiliary currents such as persistent currents.
Augmentation of persistent currents, which are small cur-
rents that persist after most of the sodium channels have
inactivated, is often accompanied by augmentation of
resurgent current, which occurs after the channels typi-
cally are inactivated (Theile et al., 2011; Barker et al.,
2017). This concurrent augmentation has been seen in
hippocampal neurons after induction of epilepsy in three
rodent models (Hargus et al., 2013; Barker et al., 2017;
Ottolini et al., 2017; Shao et al., 2017) and is associated
with neuronal hyperexcitability and repetitive firing (Ra-
man and Bean, 1997; Khaliq et al., 2003; Afshari et al.,
2004; Yue et al., 2005; Van Drongelen et al., 2006; Kim
et al., 2010; Hargus et al., 2013). Missense mutations at
arginines of the S4 segments in the voltage sensor do-
mains may produce an anomalous ion conduction path-
way that supports a so-called gating pore current, also
called omega current (Starace and Bezanilla, 2001, 2004;
Tombola et al., 2005). These voltage-dependent sus-
tained leak currents have been established as a cause of
the skeletal muscle disorder hypokalemic periodic paral-
ysis (Sokolov et al., 2007; Struyk and Cannon, 2007),
where 19 of 20 reported mutations are R/X substitutions in
S4 of the skeletal muscle sodium channel, Nav1.4, or of
the muscle L-type Ca channel, Cav1.1 (Cannon, 2018).
Subsequently, R/X mutations of S4 in the cardiac sodium
channel, Nav1.5, associated with dilated cardiomyopathy
and arrhythmias have been shown to support gating pore
current (Gosselin-Badaroudine et al., 2012; Moreau et al.,
2015). While site-directed mutagenesis has demonstrated
that the Nav1.2 neuronal sodium channel is capable of
conducting gating pore current (Sokolov et al., 2005), to
date, there has not been a report of a disease-associated
R/X mutation in Nav1.2 that supports a gating pore cur-
rent.
Among the Nav1.2 mutations suspected to cause epi-
lepsy in human patients with otherwise idiopathic epilep-
tic encephalopathies, R1882Q and R853Q are two of the
most commonly reported mutations (Carvill et al., 2013;
Epi4k Consortium, 2013; Nakamura et al., 2013; Howell
et al., 2015; Samanta and Ramakrishnaiah, 2015; Ko-
bayashi et al., 2016; Li et al., 2016; Trump et al., 2016;
Wolff et al., 2017). The R1882 residue is located in the
C-terminal tail of the channel, whereas R853 is a voltage-
sensing residue in the second domain of the channel (Fig.
1). The seizures resulting from the R853Q mutation are
typically refractory to the currently available antiepileptic
drugs, including sodium channel blockers that are effec-
tive in suppressing seizures generated by other SCN2A
mutations, including R1882Q, which suggests that the
pathogenic biological effects of the R853Q mutation differ
from those of the R1882Q mutation. In this study, we
examined the effects of these two mutations on the func-
tion of human Nav1.2 proteins expressed in HEK cells, to
identify mechanisms by which these mutations may be
pathogenic. We validated some of the recent findings
regarding these mutations using a different cell model
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Figure 1. Mutation locations. Secondary structure of hNav1.2 is shown. Locations of the R853Q and R1882Q mutations are labeled
with red stars and red arrows.
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(Berecki et al., 2018) and investigated the effects of these
mutations on resurgent currents and gating pore currents,
which the referenced study did not fully investigate. In
transiently transfected HEK cells, the R1882Q mutation
produced only gain-of-function effects, including robust
resurgent currents, while the R853Q mutation produced
mostly loss-of-function effects. However, we show that,
when expressed in Xenopus oocytes, the R853Qmutation
creates a gating pore, an anomalous gain, through which
small amounts of current can flow when the cell mem-
brane is hyperpolarized. The results of this study support
the hypothesis that the R1882Q mutation increases neu-
ronal excitability. It is not yet known how the loss-of-
function effects of the R853Q mutation and the gating
pore currents it causes might combine to lead to the
initiation of seizures and other neurologic sequalae, but
we discuss a few possibilities.
Materials and Methods
DNA constructs
Codon-optimized human Nav1.2 DNA constructs [wild-
type (WT), R1882Q, and R853Q] were designed in-house
and synthesized by GenScript. The amino acid sequence
for the synthesized WT hNav1.2 cDNA construct corre-
sponds with NG_008143.1 in the NCBI database. Synthe-
sized mutant constructs are identical to WT aside from the
single mutation (R1882Q or R853Q).
HEK cell culture and transient transfections
The use of HEK293T cells (hereafter referred to as HEK
cells; Dubridge et al., 1987) was approved by the Institu-
tional Biosafety Committee and followed the ethical
guidelines for the National Institutes of Health for the use
of human-derived cell lines. HEK cells were grown under
standard tissue culture conditions (5% CO2, 37°C) in
maintenance media consisting of DMEM supplemented
with 10% fetal bovine serum and 1% penicillin/strepto-
mycin. HEK cells were transfected using the calcium
phosphate precipitation method. Briefly, calcium phos-
phate-DNA mixture [2-g channel construct and 1-g
enhanced green fluorescent protein (EGFP)] was added to
cells in serum-free media for 8–17 h, after which the cells
were washed with maintenance media and the serum-free
media was replaced with maintenance media. Trans-
fected cells were identified by presence of fine particulate
coating the cells before washing and by expression of
EGFP using a fluorescent microscope. Whole-cell patch
clamp recordings were obtained 36–48 h after transfec-
tion.
HEK cell electrophysiology
Currents were measured at room temperature (22°C)
using a HEKA EPC 10 amplifier and the Pulse software
(v8.80, HEKA Elektronik) for data acquisition. Electrodes
were fabricated from 100-l calibrated pipettes (Drum-
mond Scientific Company; catalog #2-000-100; capillary
glass) and fire-polished to a resistance of 1.0–2.0 M
using a P-1000 micropipette puller (Sutter Instrument
Company). For each cell, a G seal was obtained before
breaking into the whole-cell configuration. Voltage proto-
cols were initiated 5 min after entering the whole-cell
configuration, allowing time for each cell’s cytoplasm to
equilibrate with the pipette solution, while also controlling
for time-dependent shifts in sodium channel properties.
Voltage errors were minimized by using series resistance
compensation (up to 90%), and passive leak currents
were cancelled by P/-5 subtraction. The bath solution
contained the following: 140 mM NaCl, 3 mM KCl, 1 mM
MgCl2, 1 mM CaCl2, and 10 mM HEPES, adjusted to pH
7.30 with NaOH. The pipette solution contained the fol-
lowing: 130 mM CsF, 10 mM NaCl, 10 mM HEPES, and 1
mM CsEGTA, adjusted to pH 7.30 with CsOH. Nav
accessory subunits were not co-transfected with the
Nav1.2 subunit, which functions independently as a
channel, due to the variability that this would introduce
into the experiments and the lack of information regarding
which Nav subunits are associated with the Nav1.2
subunits in the affected neurons in the brain. Instead,
Nav4 peptide (KKLITFILKKTREK-OH, used at 200 M;
Biopeptide Co., Inc.), which corresponds to part of the
C-terminal tail of the full-length Nav 4 subunit, was
included in the pipette solution to induce/amplify the re-
surgent currents. This peptide has been shown to induce
resurgent currents in HEK cells expressing voltage-gated
sodium channels, while, for unknown reasons, the full-
length Nav4 peptide is not sufficient to produce resur-
gent currents in HEK cells expressing voltage-gated
sodium channels (Chen et al., 2008; Aman et al., 2009).
HEK cell voltage protocols
All HEK cells were held at –100 mV.
Measures pertaining to transient current size, voltage-
dependent activation, and persistent current were taken
from a voltage protocol consisting of 50-ms test pulses to
voltages from –80 to 60 mV, in 5-mV steps (Fig. 2C,
top). Peak current amplitudes, for each voltage, were
measured as the minimum value of the current over the
entirety of the test pulse. Current densities were calcu-
lated by dividing raw current amplitudes by the membrane
capacitance value of each cell. The reversal potential was
estimated, for each cell, by extrapolation of the ascending
limb of the currentvoltage (IV) curve. The conductance
values were then calculated and normalized within each
cell. Persistent currents were measured, in Pulsefit (v8.80,
HEKA Elektronik), as an average of the current amplitude
over the last 10% of the test pulse, from 40 to 50 ms.
Inactivation was measured by a 500 ms prepulse step
to voltages from –130 to 10 mV, in 10-mV steps, fol-
lowed by a 20-ms test pulse to 10 mV (Fig. 2C, bottom).
As with the activation protocol, peak transient current
amplitude, for each voltage, was measured as the mini-
mum value of the current over the entirety of the test
pulse.
Resurgent currents were elicited by a 20-ms pulse to
30 mV, followed by a 50-ms repolarization step of volt-
ages from 10 to –65 mV (Fig. 3D, top). The resurgent
current peak amplitude was measured, in Pulsefit, as the
minimum value of the current elicited during the repolar-
ization step.
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Subcloning and expression in oocytes
For expression of hNav1.2 in oocytes, the SCN2A gene
was cut from the pcDNA3.1 vector using the restriction
enzymes NotI and NheI and subcloned into the pGEMHE-
membrane-mEGFP plasmid (a gift from Melina Schuh,
Addgene plasmid #105526; http://n2t.net/addgene:105526;
RRID:Addgene_105526; Clift et al., 2017), replacing the
EGFP gene with the SCN2A gene. The human 1 subunit,
also in pGEMHE (Struyk and Cannon, 2007), was co-
expressed with hNav1.2 because it normalizes the inac-
tivation kinetics of voltage-gated sodium channels
expressed in Xenopus oocytes (Patton et al., 1994). Com-
plementary RNAs were synthesized in vitro with the
mMessage mMachine transcription kit (Ambion). Oocytes
were injected with 50 ng of the hNav1.2 WT or R853Q
transcript plus 50 ng of the 1 subunit (four-fold molar
excess).
Oocyte maintenance
Oocytes were harvested from three female Xenopus
laevis under MS222 anesthesia, in accordance with the
guidelines established by the University of California, Los
Angeles animal care committee’s regulations. After defol-
liculation in collagenase Type I at room temperature for
2 h, oocytes were injected with cRNA and stored at
18°C in 0.5  Leibovitz’s L-15 medium (Gibco) supple-
mented with 1% horse serum, 100 U/ml penicillin, 100
g/ml streptomycin, and 100 g/ml amikacin.
Oocyte electrophysiology
Currents were recorded 3–6 d after injection using a
cut-open oocyte voltage-clamp with the CA-1B amplifier
(Dagan Corp.) in headstage clamp mode, as previously
described (Struyk and Cannon, 2007). The extracellular
solution (upper and middle chambers) contained the fol-
lowing: 115 mM Na-methanesulfonate, 3 mM K-meth-
anesulfonate, 4 mM Ca-acetate, 10 mM HEPES, 0.1 mM
ouabain, and 0.005 mM tetrodotoxin (TTX), pH 7.4 with
NaOH. The internal solution (lower chamber) contained
the following: 120 mM K-methanesulfonate, 10 mM
EGTA, and 10 mM HEPES, pH 7.4 with methanesulfonic
acid. The lower surface of the oocyte was permeabilized
by brief exposure to internal solution supplemented with
0.1% saponin.
Oocyte voltage protocol(s)
To record gating pore current, an oocyte was held at
–100 mV and a series of 200-ms voltage steps from –140
to 40 mV was applied. No on-line leak subtraction was
used. Instead, a linear fit of the (total) steady-state IV for
test potentials from –20 to 10 mV obtained to estimate
the nonspecific linear current, which was subtracted to
obtain the gating pore current. Charge displacement cur-
rent was recorded by application of a series of 20-ms test
depolarizations from –140 to 40 mV from a holding
potential of –100 mV. The membrane capacitance was
analog compensated with the amplifier circuitry, and the
residual linear leakage current suppressed by P/N on-line
Figure 2. The R1882Q mutation has no effect on transient current size and impairs inactivation. A, Representative raw current trace
families elicited by voltage steps from –80 to 60 mV. B, Average transient current densities elicited by voltage steps from –80 to
60 mV (n 40 WT cells, n 25 R1882Q cells). C, Voltage stimulation protocols used for collection of activation (top) and inactivation
(bottom) data from HEK cells. D, Activation curves. Conductance was calculated as G/Gmax, where G  I/(Vm-Vrev), Vrev  reversal
potential, and Gmaxmaximum inward conductance across all tested voltages (n 41 WT cells, n 27 R1882Q cells). E, Inactivation
curves. Fraction available was calculated as I/Imax for each cell at each voltage step (n  40 WT cells, n  23 R1882Q cells). F, Time
constants of fast inactivation were calculated by fitting the decay portion of each current trace to a single-exponential equation in
PulseFit (HEKA; n  41 WT cells, n  27 R1882Q cells). WT data are represented by black circles, and R1882Q data by red triangles,
in B, D–F. Error bars (SEM) are included for every data point in parts B, D–F; please note that many error bars are small and are thus
obscured by the symbols. Asterisks indicate significance level (p  0.05, p  0.0001).
Figure Contributions: Emily Mason performed data collection and analysis.
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leak subtraction of the current elicited by a depolarization
from –120 to –100 mV. The charge displacement current
was integrated digitally to obtain on-gating charge, Qon.
Statistics and analysis
Electrophysiological data were analyzed using Pulsefit
(v.8.80, HEKA Elektronik), Microsoft Excel, Origin (v9.1,
OriginLab Corp.), and GraphPad Prism (v.7.03, GraphPad
Software, Inc.). All data points are presented as mean 	
SEM, and n is the number of cells from which contributing
data were collected. Current density and conductance
were calculated as previously described (Cummins et al.,
1994; also, see above, HEK cell voltage protocols). Acti-
vation and inactivation midpoints were estimated by fit-
ting the conductance and inactivation curves to a
Boltzmann equation in Pulsefit. Inactivation time con-
stants were estimated by fitting the decay portion of each
sodium current trace to a single-exponential equation in
Pulsefit.
The normality of data distribution was evaluated with
the Shapiro–Wilk normality test. If the data were normally
distributed, a parametric test was used; if the data were
not normally distributed, a nonparametric test was used.
For data comparisons spanning multiple voltages, a two-
way ANOVA with the Sidak’s multiple comparisons test
was used. When a single measure was compared be-
tween the WT and mutant groups, the data were com-
pared with one-way ANOVAs. If the data were normally
distributed, an ordinary one-way ANOVA with Dunnett’s
multiple comparisons test was used; if the data were not
normally distributed, the nonparametric Kruskal–Wallis
with Dunn’s multiple comparisons test was used. Statis-
tical significance was set at   0.05. Unless otherwise
stated, p values reported for ANOVAs are the p values
obtained from the post hoc test, and a significant p value
(p  0.05) was obtained in the ANOVA test. Specific
statistical results are shown in Table 1. For all figures, p
 0.05, p  0.01, p  0.001, and p  0.0001.
When data for the R1882Q mutant, the R853Q mutant,
and the WT channel were collected concurrently, ANOVA
or nonparametric tests were used to analyze the HEK cell
data. The values for each mutant were compared to the
WT channel values, and thus Dunn’s or Dunnett’s post
hoc tests were used to determine significant differences
between mutant and WT channel values. Data from
oocytes only included two groups, WT and R853Q, and
therefore a nonparametric Mann–Whitney test was used
to compare Qmax values obtained from oocytes.
Results
Effects of the R1882Q mutation on channel function
The R1882Q mutation impairs fast inactivation
To investigate the functional effects of the R1882Q
mutation on hNav1.2 channel function, the biophysical
properties of WT and R1882Q mutant voltage-gated so-
Figure 3. The R1882Q mutation enhances persistent and resurgent currents. A, Representative raw current traces from a voltage step
to –15 mV. Persistent current (box and inset) was measured as the average current over the last 10% (i.e., 5 ms) of the voltage step.
B, Average persistent current densities during the last 10% of voltage steps from –80 to 60 mV (n  39 WT cells, n  25 R1882Q
cells). C, Average persistent current amplitudes normalized to maximum peak transient current amplitudes (n  40 WT cells, n  27
R1882Q cells). D, Resurgent current voltage protocol (top) and representative resulting raw current trace families (middle and bottom).
E, Average peak resurgent current densities over a range of voltages from –80 to 60 mV (n  39 WT cells, n  25 R1882Q cells).
F, Average peak resurgent current amplitudes normalized to maximum peak transient current amplitudes (n  39 WT cells, n  25
R1882Q cells). For B, C, E, F, values were calculated for each individual cell and averaged for each group. WT data are represented
by black circles, and R1882Q data by red triangles, in B, C, E, F. Error bars (SEM) are included for every data point in parts B, C, E,
F; please note that many error bars are small and are thus obscured by the symbols. Asterisks indicate significance level (p  0.05,
p  0.01, p  0.0001).
Figure Contributions: Emily Mason performed data collection and analysis.
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dium channels were characterized using whole-cell volt-
age clamp electrophysiology. The channel constructs
were transiently expressed in HEK cells, which we have
found to express little to no endogenous voltage-gated
sodium current (–207.1 	 33.64 pA, n  10). Therefore,
most of the voltage-gated inward current that we see,
which, on average, is many times the amplitude of the
average endogenous current, can be attributed to the WT
or R1882Q channels for which the DNA was transfected.
The R1882Q mutation had no effect on the average
peak transient current density elicited by voltage steps
between –80 and 65 mV (Fig. 2A,B, p 
 0.40 at all
tested membrane potentials). It also had no effect on the
average maximum peak transient current amplitude (an
average of the maximum peak transient current amplitude
values for individual cells, n  41 WT, n  27 R1882Q; p

 0.99), or the average maximum peak transient current
density (an average of the maximum peak transient cur-
rent density values for individual cells, n  40 WT, n  22
R1882Q; p  0.80) when transiently expressed in HEK
cells. Thus, the R1882Q mutation does not alter transient
hNav1.2 current amplitudes or densities in HEK cells.
The voltage dependence of activation and inactivation
were assessed using step depolarizations as seen in the
voltage protocols (Fig. 2C). The R1882Q mutation pro-
duced no significant shift in the conductance curve of
Nav1.2, compared to WT (Fig. 2D, p 
 0.40 at all tested
membrane potentials) and had no effect on the average
midpoint of activation (WT –26.50 	 1.48 mV, R1882Q
–24.77 	 2.76 mV, n  41 WT, n  24 R1882Q; one-way
ANOVA p  0.79). The R1882Q mutation produced a
significant depolarizing shift in the fast inactivation curve
(Fig. 2E, p 0.0001 from –70 to –50 mV, p 0.040 at –40
mV), which was reflected in the depolarization of the
Table 1. Statistical table
Figure Data type N (group) Statistical test(s) Power/significance
2B Each data point represents
the group average value
at that particular
membrane potential
40 (WT cells), 25
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q, p 
 0.40 at all tested membrane
potentials
2D Each data point represents
the group average value
41 (WT cells), 27
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0004, WT vs R1882Q, p 
 0.40 at all tested membrane
potentials
2E Each data point represents
the group average value
40 (WT cells), 23
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001; WT vs R1882Q p  0.0891 at –80 mV, p  0.0001
from –70 to –50 mV, p  0.0398 at –40 mV
2F Each data point represents
the group average value
41 (WT cells), 27
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q p  0.0001 at –20 and –15 mV, p 
0.0185 at –10 mV
3B Each data point represents
the group average value
39 (WT cells), 25
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q p  0.0001 from –50 to –25 mV, p 
0.0016 at –20 mV, p  0.0526 at –15 mV
3C Each data point represents
the group average value
40 (WT cells), 27
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q p  0.0003–0.017 from –45 to –25
mV
3E Each data point represents
the group average value
39 (WT cells), 25
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q, p  0.0084 – 0.0466 from –35 to
–20 mV
3F Each data point represents
the group average value
39 (WT cells), 25
(R1882Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R1882Q, p  0.0053 – 0.0446 from –35 to
–20 mV
4B Each data point represents
the group average value
40 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001; WT vs R853Q p  0.0250 () at –30 mV, p  0.0037
() at –25 mV, p  0.0002 () at –20 mV, p  0.0001 () from –15 to
5 mV, p  0.0005 () at 10 mV, p  0.0006 () at 15 mV, p 
0.0056 () at 20 mV, p  0.0160 () at 25 mV, p  0.0293 () at 30
mV, p  0.0733 (ns) at 35 mV
4D Each data point represents
the group average value
41 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0004, WT vs R853Q, p 
 0.99 at all tested membrane
potentials
4E Each data point represents
the group average value
40 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q, p  0.0001 at –70 and –60 mV
4F Each data point represents
the group average value
41 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q p 
 0.99 at all tested membrane
potentials
5B Each data point represents
the group average value
39 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q p  0.0028 – 0.0500 from –35 to 5
mV, p  0.0670 (ns) at 10 mV
5C Each data point represents
the group average value
40 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q p 
 0.10 at all tested membrane
potentials
5E Each data point represents
the group average value
39 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q p  0.0058 – 0.0137 from –40 to –30
mV
5F Each data point represents
the group average value
39 (WT cells), 16
(R853Q cells)
Two-way ANOVA, Dunnett’s multiple
comparisons test
Column factor p  0.0001, WT vs R853Q p  0.0972 at –35 mV, p 
 0.10 at all
tested membrane potentials
6C Each data point represents
the group average value
5 (WT cells), 8
(R853Q cells)
Two-way ANOVA with Sidak’s multiple
comparisons test
Column factor p  0.0001; multiple comparisons p  0.0745 at –20 mV, p 
0.0026 at –10 mV, p  0.0001 at 0 mV, p  0.0001 from 10 to 40 mV
6D Each data point represents
the group average value
5 (WT cells), 8
(R853Q cells)
Two-way ANOVA with Sidak’s multiple
comparisons test
Column factor p  0.1488
7A–F Representative single-cell
data
1 (WT cell), 1 (R853Q
cell)
No statistical tests performed
8 Representative single-cell
data
1 (WT cell), 1 (R853Q
cell)
No statistical tests performed
9A Each data point represents
values from a single cell




R853Q: slope  –118 nC/nA, Pearson’s R  –0.974, R2 (adjusted)  0.943
9B Each data point represents
the group average value
6 (WT cells), 11
(R853Q cells)
Two-way ANOVA with Sidak’s multiple
comparisons test
Column factor p  0.0001; multiple comparisons p  0.0001 from –120 to –70
mV, p  0.0002 at –60 mV, p  0.0359 at –50 mV; p 
 0.5000 for all other
membrane potentials
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average inactivation midpoint (WT –65.01 	 1.27 mV,
R1882Q –57.34 	 2.05 mV, n  40 WT, n  20 R1882Q;
p  0.0017). The R1882Q mutation also slowed inactiva-
tion, as evidenced by increased inactivation time con-
stants at voltages from –20 to 10 mV (Fig. 2F, p 
0.0001 at –20 and –15 mV, p  0.0185 at –10 mV). Thus,
the R1882Q mutation has no effect on hNav1.2 activation
but impaired inactivation in HEK cells.
The R1882Q mutation increases persistent and resur-
gent currents
The persistent component of the transient current was
measured as the average current amplitude during the
last 10% of each depolarization pulse in the activation
protocol (Fig. 2C, top). The R1882Q mutation increased
average persistent current amplitudes and densities at
voltages from –65 to 5 mV (Fig. 3A,B, p  0.0001 from
–50 to –25 mV, p  0.0016 at –20 mV, p  0.0526 at –15
mV). When analyzed at a single voltage of –30 mV, the
average persistent current amplitude was increased for
the R1882Q mutant, compared to WT (WT, –44.97	 4.15
pA, R1882Q –100.80 	 16.53 pA, n  40 WT, n  27
R1882Q; p  0.029). To normalize the persistent current
amplitudes to overall expression levels, we also plotted
persistent current amplitude as a percentage of the max-
imum peak transient current amplitude of the cells (value
calculated for each individual cell, averages plotted in Fig.
3C). This analysis also revealed an increase in persistent
current for the R1882Q mutant channel at most voltages
from –65 to 5 mV (Fig. 3C, p  0.05 from –35 to –20
mV), compared to the WT channel. When the persistent
current, as percentage of transient current, was analyzed
at –30 mV, the significant increase caused by the R1882Q
mutation was again observed (WT 0.57	 0.05%, R1882Q
1.15 	 0.13, n  40 WT, n  27 R1882Q; p  0.0001).
Thus, the R1882Q mutation enhances persistent hNav1.2
currents in HEK cells.
Resurgent sodium currents have not been studied with
Nav1.2 disease mutations, although they have been as-
sociated with other diseases (Jarecki et al., 2010; Hargus
et al., 2011; Patel et al., 2016; Tanaka et al., 2016; Xiao
et al., 2019). To induce resurgent current through Nav1.2
in HEK cells, the Nav4 peptide (200 M) was included in
the pipette solution. Cells were depolarized to 30 mV
briefly, to open the channel and allow the peptide time to
block the central pore, followed by a longer repolarization
to voltages ranging from –65 to 10 mV (Fig. 3D, top).
Resurgent current occurs during the repolarization step,
after the transient current is inactivated, when the peptide
unbinds and a small inward current occurs between the
unbinding of the peptide and the binding of the inactiva-
tion particle to the pore. The R1882Q mutation increased
average resurgent current amplitudes and densities at
voltages from –65 to 0 mV (Fig. 3D,E, p  0.0082 –0.046
from –35 to –20 mV). When analyzed at a single voltage of
–30 mV, the average maximum resurgent current ampli-
tude was increased for the R1882Q mutant, compared to
WT [WT –178.40 	 15.33 pA, R1882Q –284.80 	 45.71
pA, n  39 WT, n  25 R1882Q; Kruskal–Wallis test, p 
0.0001, Dunn’s multiple comparisons test, WT vs
R1882Q, p  0.3432 (ns)]. When the resurgent current, as
percentage of transient current, was analyzed at –30 mV,
the R1882Q mutation still increased the value, compared
to WT (WT 2.39	 0.18 %, R1882Q 3.35	 0.31 %, n 39
WT, 25 R1882Q; p  0.0050). When normalized to the
maximum peak transient current amplitudes for individual
cells, the resurgent current was, again, increased by the
R1882Q mutation at voltages from –65 to –5 mV (Fig. 3F,
p  0.0053 – 0.0446 from –35 to –20 mV). Thus, the
R1882Q mutation enhances hNav1.2 resurgent currents
in HEK cells.
Effects of the R853Q mutation on channel function
The R853Q mutation decreases transient current and
enhances fast inactivation
The R853Q mutation decreased the average peak tran-
sient current density, compared to WT (Fig. 4A,B, p 
0.05 from –30 to 30 mV), as well as the average maxi-
mum peak transient current amplitude (WT –8.75 	 0.76
nA, R853Q –3.82 	 0.54 nA, n  41 WT, n  16 R853Q;
p  0.0045). This mutation also resulted in a reduction of
maximum peak transient current density (WT–0.55	 0.05
nA/pF, R853Q –0.28 	 0.04 nA/pF, n  40 WT, n  15
R853Q; p  0.0033). Thus, the R853Q mutation de-
creases transient hNav1.2 current amplitudes and densi-
ties in HEK cells.
The same voltage protocols that were used to study
activation and inactivation in the R1882Q mutant were
used to study these parameters for the R853Q mutant
(Fig. 4C). The R853Q mutation did not significantly alter
the voltage-dependence of activation for hNav1.2 chan-
nels (in HEK cells; Fig. 4D, p 
 0.99 at all tested mem-
brane potentials). This was supported by a lack of
significant difference in average estimated activation mid-
points (WT –26.5 	 1.48, R853Q –25.11 	 1.81, n  41
WT, n  16 R853Q; one-way ANOVA p  0.79) but it
produced a hyperpolarizing shift in both the voltage-
inactivation relationship (Fig. 4E, p  0.0001 at –70 and
–60 mV) and the average estimated inactivation midpoint
(WT –65.01 	 1.27 mV, R853Q –71.46 	 1.62 mV, n  40
WT, n  16 R853Q; p  0.016). The speed of fast inacti-
vation, measured as a time constant, was unaltered by
this mutation (Fig. 4F, p 
 0.99 at all tested membrane
potentials). Thus, the R853Q mutation has no effect on
hNav1.2 activation but enhances inactivation in HEK cells.
The R853Q mutation decreases persistent and resurgent
currents
Persistent current was measured in the same manner
for the R853Q mutant channel as for the R1882Q mutant
and WT channels. As shown in the representative traces
(Fig. 5A), the R853Q mutation reduced the average inward
persistent current amplitudes and densities between volt-
ages of –60 to 10 mV (Fig. 5B, p  0.0028–0.05 from
–35 to 5 mV). This reduction in persistent current was
further supported by a reduction in the average persistent
current amplitude during a –30-mV depolarization (WT
–44.97 	 4.15 pA, R853Q –12.78 	 4.27 pA, n  40 WT,
n  16 R853Q; p  0.0008). When normalized to the
maximum peak transient current amplitudes for individual
cells, the persistent current was reduced, although non-
significantly, by the R853Q mutation, compared to per-
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sistent current in the WT channel (Fig. 5C, p 
 0.10 at all
tested membrane potentials). This reduction was sup-
ported by analysis of the average persistent current dur-
ing a –30-mV step, as percentage of peak transient
current, which showed a significant reduction in this value
with the R853Q mutation, compared to WT (WT 0.57 	
0.05%, R853Q 0.26 	 0.10, n  40 WT, n  16 R853Q; p
 0.037). Thus, the R853Q mutation decreases persistent
hNav1.2 currents in HEK cells.
Resurgent current was measured in the same manner
for the R853Q mutant channel as for the R1882Q mutant
and WT channels (protocol in Fig. 5D, top). Compared to
cells expressing WT hNav1.2 channels, cells expressing
R853Q mutant channels exhibited a significant reduction
in average resurgent current amplitudes and densities
(Fig. 5D,E, p  0.0058 – 0.0137 from –40 to –30 mV),
which also manifested as a reduction when the maximum
peak resurgent current amplitudes were normalized to the
maximum peak transient current amplitudes for individual
cells (Fig. 5F, p  0.0972 at –35 mV, p 
 0.10 at all tested
membrane potentials). These results were supported by
analysis of the average resurgent current amplitudes dur-
ing a –30-mV pulse, which revealed a significant reduction
in the average peak resurgent current amplitude (WT
–178.40 	 15.33 pA, R853Q –61.33 	 7.26, n  39 WT,
n  16 R853Q; p  0.0001) and in the average peak
resurgent current amplitude expressed as a percentage of
peak transient current amplitude (WT 2.39 	 0.18 %,
R853Q 1.55 	 0.11 %, n  39 WT, 16 R853Q; p 
0.0389). Thus, the R853Q mutation decreases resurgent
hNav1.2 currents in HEK cells.
The R853Q mutation forms a gating pore that passes
current at negative membrane potentials
All of our data up to this point is consistent with the
hypothesis that the R853Q mutation confers a loss of
function on the hNav1.2 channel. Since the seizures and
choreoathetosis (a specific form of irregular involuntary
movements) associated with this mutation suggest a pos-
sible neuronal gain of function effect, we hypothesized
that this mutation increases channel activity via the for-
mation of a gating pore conductance. Such a pore, which
is structurally distinct from the central pore, can allow
some monovalent cations to leak into the cell through the
Domain II voltage sensor, which contains the R853Q mu-
tation (Fig. 6A,B).
To assess the effects of the R853Q mutation on the
gating pore current, cells expressing WT or R853Qmutant
hNav1.2 were treated with TTX and subjected to a series
of voltage steps. Such experiments in HEK cells yielded
inconsistent results which were difficult to interpret. Since
Xenopus oocytes are much larger and can express more
Figure 4. The R853Q mutation reduces transient current size and enhances inactivation. A, Representative raw current trace families
elicited by voltage steps from –80 to 60 mV. B, Average transient current densities elicited by voltage steps from –80 to 60 mV
(n 40 WT cells, n 16 R853Q cells). C, Voltage stimulation protocols used for collection of activation (top) and inactivation (bottom)
data from HEK cells. D, Activation curves. Conductance was calculated as G/Gmax, where G  I/(Vm-Vrev), Vrev  reversal potential,
and Gmax  maximum inward conductance across all tested voltages (n  41 WT cells, n  16 R853Q cells). E, Inactivation curves.
Fraction available was calculated as I/Imax for each cell at each voltage step (n  40 WT cells, n  16 R853Q cells). F, Time constants
of fast inactivation were calculated by fitting the decay portion of each current trace to a single-exponential equation in PulseFit
(HEKA; n  41 WT cells, n  16 R853Q cells). WT data are represented by black circles, and R853Q data by red squares, in B, D–F.
Error bars (SEM) are included for every data point in parts B, D–F; please note that many error bars are small and are thus obscured
by the symbols. Asterisks indicate significance level (p  0.05, p  0.0001).
Figure Contributions: Emily Mason performed data collection and analysis.
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copies of the transfected Nav channel, the peak current
amplitude in oocytes is much larger (1000–10,000)
than that recorded from HEK cells. We reasoned that
because, in oocytes, all currents, including gating pore
current, are amplified, this amplification would allow rig-
orous quantification of any differences in gating pore
current amplitude between WT and R853Q mutant
hNav1.2 channels. The optimized hNav1.2 WT and R853Q
mutant channel constructs were subcloned from the
pcDNA3.1 vector into a pGEMHE vector that could be
used for sodium channel expression in oocytes. To esti-
mate relative plasma membrane expression levels of WT
and R853Q mutant hNav1.2 channels, the average max-
imal gating charge (Qmax) of oocytes expressing WT or
R853Q mutant hNav1.2 channels was measured in the
presence of TTX. The Qmax was significantly reduced by
the R853Q mutation, compared to WT (Fig. 6C, WT 0.85
	 0.12 nC, n  5; R853Q 0.44 	 0.06 nC, n  6; p 
0.0001 at all voltages positive to 0 mV). The magnitude of
this reduction of Qmax (50%) suggests that the plasma
membrane expression level of the channels is reduced by
the R853Q mutation, consistent with the reduced ampli-
tude of the transient inward sodium current in HEK cells.
Normalizing the Q(V) curves to Qmax for each cell and
plotting the average across cells revealed no significant
change in the midpoint or slope of the gating charge-
voltage relationship between WT-expressing and R853Q-
expressing oocytes (Fig. 6D). This suggests that there is
no significant difference in the voltage dependence of
total gating charge movement between WT and R853Q
mutant channels.
To measure gating pore current, the total leak current in
oocytes expressing WT or mutant hNav1.2 was measured
over a range of membrane potentials in the presence of
TTX, which blocked the central pore and prevented tran-
sient current conduction (–120 to 40 mV; Fig. 7A–D). to
isolate the gating pore current, the average nonspecific
leak current was subtracted from the total leak current.
The average nonspecific leak was estimated by fitting the
steady-state currentvoltage (I-V) curve (range –20 to
10 mV, end of 200-ms pulse) with a line (Fig. 7C,D,
dotted lines) and subtracted from the total leak current
(Fig. 7C,D, data points) to generate gating pore current
I-V curves for WT-expressing and R853Q-expressing
oocytes (Fig. 7E,F). Compared to WT-expressing oocytes,
R853Q-expressing oocytes demonstrated an inwardly-
rectifying current that diverges from the nonspecific leak
current at hyperpolarized potentials (Fig. 7E,F). We attri-
bute this anomalous inward-rectifying current to the for-
mation of a gating pore in the mutant channel, as
supported by dramatically increased current amplitude in
the presence of extracellular guanidinium (Fig. 8), as pre-
viously reported for gating pore currents in R/X mutations
of S4 in Nav1.4 (Sokolov et al., 2010).
To further confirm that the inwardly-rectifying current in
the R853Q mutant channels is conducted by the gating
pore, and not an endogenous conductance, the Qmax for
each cell was plotted against the measured gating pore
Figure 5. The R853Q mutation reduces persistent and resurgent currents. A, Representative raw current traces from a voltage step
to –15 mV. Persistent current (box and inset) was measured as the average current over the last 10% (i.e., 5 ms) of the voltage step.
B, Average persistent current densities during the last 10% of voltage steps from –80 to 60 mV (n  39 WT cells, n  16 R853Q
cells). C, Average persistent current amplitudes normalized to maximum peak transient current amplitudes (n  40 WT cells, n  16
R853Q cells). D, Resurgent current voltage protocol (top) and representative resulting raw current trace families (middle and bottom).
E, Average peak resurgent current densities over a range of voltages from –80 to 60 mV (n  39 WT cells, n  16 R853Q cells).
F, Average peak resurgent current amplitudes normalized to maximum peak transient current amplitudes (n  39 WT cells, n  16
R853Q cells). For B, C, E, F, values were calculated for each individual cell and averaged for each group. WT data are represented
by black circles, and R853Q data by red squares, in B, C, E, F. Error bars (SEM) are included for every data point in parts B, C, E,
F; please note that many error bars are small and are thus obscured by the symbols. Asterisks indicate significance level (p  0.05).
Figure Contributions: Emily Mason performed data collection and analysis.
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current at –120 mV. This plot (Fig. 9A) revealed a linear
correlation between inward current amplitudes and the
corresponding maximal gating charge displacement in
individual oocytes for the R853Q mutant channel, but not
for the WT channel. This suggests that a gating pore
current that is dependent on channel density is present in
the R853Q mutant form of hNav1.2 but essentially absent
in the WT form.
To facilitate the comparison of gating pore currents in
oocytes with different levels of channel expression on the
plasma membranes, leak-subtracted currents were normal-
ized to Qmax for each oocyte. The average normalized I-V
relationships of WT-expressing and R853Q-expressing
oocytes revealed a substantial increase in hyperpolarization-
activated inward current in R853Q-expressing oocytes com-
pared to WT-expressing oocytes (Fig. 9B). These data
provide strong support for the theory that a gating pore
current exists in the R853Q mutant channel at membrane
potentials negative to –30 mV.
Discussion
Mutations in neuronal voltage-gated sodium channel
isoforms are increasingly being identified as underlying
otherwise idiopathic cases of epilepsy. Although over 150
different mutations in the Nav1.2 gene, SCN2A, have
been reported as likely causes of epilepsy, biophysical
characterization of only about two dozen of these muta-
tions have been reported to date. Eleven have been
Figure 6. R853Q creates a gating pore and reduces channel surface expression. A, B, Nav1.2 channel in resting state (Domains I and
III, N-terminal domain, and C-terminal domain not shown). A, In the resting state, the WT Nav1.2 is essentially impermeable. B, In the
resting state, the mutation of arginine 853 to glutamine creates a small aqueous pathway that is blocked when the channel transitions
to an open state. Since this channel (i.e., the gating pore) is structurally distinct from the central pore of Nav1.2, current through it can
be isolated by blocking the central pore with TTX. C, Average gating charge (Q) values measured from oocytes expressing either WT
(black squares) or R853Q (red circles) hNav1.2. The Qmax for each group was calculated as the average Q value at 40 (n  5 WT
cells, n  8 R853Q cells). D, Voltage dependence of gating charge movement is shown as a normalized gating charge-voltage
relationship (n  5 WT cells, n  8 R853Q cells). Average gating charge (Q) across a range of membrane potentials were normalized
to the average Qmax value for each group. WT data are represented by black squares, and R853Q data by red circles, in C, D. Error
bars (SEM) are included for every data point in parts C, D; please note that many error bars are small and are thus obscured by the
symbols. Asterisks indicate significance level (p  0.01, p  0.001, p  0.0001).
Figure Contributions: Fenfen Wu performed data collection and analysis.
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Figure 7. R853Q creates nonlinear leak current. Single-cell representative data (n  1 WT, n  1 R853Q). A, B, Representative
raw leak current traces measured from oocytes expressing either WT (black) or R853Q (red) hNav1.2 show inward rectification
at hyperpolarized potentials for R853Q that was not observed for WT hNav1.2. Voltage steps over a range from –120 mV to 40
mV were applied from a holding potential of –100 mV. C, D, Leak I-V relationships of the representative cells. Dashed line shows
the background linear leakage current, estimated by fitting a line to the steady-state IV plot in the range –10 to 10 mV. Notice
that the holding current at –100 mV is entirely from the linear nonspecific leak in WT, whereas for the representative R853Q
oocyte the holding current is almost entirely from the contribution of the non-linear inward rectifying component. E, F,
Subtraction of the linear background current reveals strong inward rectification for R853Q (red) and low-amplitude nonspecific
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shown to have only gain-of-function effects, six have
primarily loss-of-function effects, and five have mixed
gain- and loss-of-function effects. However, our study is
the first to identify enhanced resurgent currents and gat-
ing pore currents as effects of SCN2A disease mutations.
Among the Nav1.2 mutations suspected to cause epi-
lepsy in human patients, R1882Q and R853Q are two of
the most commonly reported mutations (Wolff et al.,
2017). The R1882Q mutation has been reported in numer-
ous patients diagnosed with early onset epileptic enceph-
alopathies (6/7 reported onset of 1 d; Carvill et al., 2013;
Howell et al., 2015; Trump et al., 2016; Wolff et al., 2017).
In contrast, patients with the R853Q mutation were diag-
nosed with West syndrome or unspecified epileptic en-
cephalopathy, and most or all of these patients had late
onsets of seizures (six months to three years); and many
exhibit dystonia and/or choreoathetosis (Epi4k Consor-
tium, 2013; Nakamura et al., 2013; Samanta and Ra-
makrishnaiah, 2015; Kobayashi et al., 2016; Li et al., 2016;
Wolff et al., 2017).
R1882Q mutation effects on hNav1.2 function and
predicted effects on neuronal excitability
Four different mutations of the R1882 residue in Nav1.2
have been reported as being putatively pathogenic in
epilepsy cases (R1882L, R1882P, R1882G, and R1882Q;
Carvill et al., 2013; Baasch et al., 2014; Howell et al., 2015;
Schwarz et al., 2016; Trump et al., 2016; Parrini et al.,
2017; Wolff et al., 2017). As of yet, the biophysical effects
of the R1882L and R1882P mutations have not been
studied. The R1882G mutation, which, like R1882Q, neu-
tralizes the positive residue, has been shown to cause
gain-of-function effects on Nav1.2 channels in tsA201
cells (Schwarz et al., 2016).
A recent study using Chinese hamster ovary (CHO) cells
transiently transfected with hNav1.2 revealed that the
R1882Q mutation causes a depolarizing shift in the volt-
age dependence of fast inactivation, enhances persistent
currents, and slows fast inactivation, compared to the WT
channel (Berecki et al., 2018). The results of the present
continued
variance for WT (black). WT data are shown in black (A, C, E); R853Q data in red (B, D, F).
Figure Contributions: Fenfen Wu performed data collection and analysis.
Figure 8. R853Q-induced gating pore is permeable to guani-
dinium. Single-cell representative data (n  1 WT, 1 R853Q).
Leak currents in oocytes expressing either WT (black squares) or
R853Q (red circles) hNav1.2 in the absence (empty symbols) and
presence (filled symbols) of guanidinium (Gu), a cation believed
to be permeant to the gating pore created by the R853Q muta-
tion in hNav1.2.
Figure Contributions: Fenfen Wu performed data collection and
analysis.
Figure 9. R853Q creates gating pore current. A, Distance of gating charge movement (Qmax) was plotted against the gating pore
current amplitude measured at –120 mV for each cell (n  6 WT cells, n  11 R853Q cells). B, Average leak-subtracted (i.e., gating
pore) current was normalized to Qmax for each cell and the normalized gating pore I-V relationships for WT (black squares) and R853Q
(red circles) were plotted (n  6 WT cells, n  11 R853Q cells). Error bars (SEM) are included for every data point in part B; please
note that many error bars are small and are thus obscured by the symbols. Asterisks indicate significance level (p  0.05, p 
0.001, p  0.0001).
Figure Contributions: Fenfen Wu performed data collection and analysis.
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study corroborate those findings. Additionally, we show
that this mutation substantially enhances resurgent cur-
rents in HEK cells, whereas the CHO cell study did not
address the possibility of changes in resurgent current
due to this mutation. In CHO cells, the R1882Q mutation
was also reported to increase peak current density and
hyperpolarize the voltage dependence of activation (Be-
recki et al., 2018), but we did not observe those effects in
our experiments. All of the observed changes enhance
Nav1.2 channel function, which is predicted to increase
neuronal excitability. This prediction was previously
tested using a dynamic action potential clamp model. This
approach fuses voltage clamp of CHO cells transiently
expressing Nav1.2 channels with a computer model of a
typical cortical neuron axon initial segment and predict
that R1882Q would chronically depolarize neurons and
increase their action potential firing activity (Berecki et al.,
2018). Importantly, this model system did not incorporate
resurgent current mechanisms, which are predicted to
further enhance the pro-excitatory impact of the R1882Q
mutation.
Resurgent currents have been identified as drivers of
both repetitive action potential activity and spontaneous
action potential generation (Raman and Bean, 1997;
Khaliq et al., 2003; Bant and Raman, 2010; Barbosa et al.,
2015; Xiao et al., 2019). Resurgent currents are also en-
hanced by pro-excitatory disease mutations in other
voltage-gated sodium channel isoforms which are asso-
ciated with pain, myotonia congenital, long-QT syndrome,
and SCN8A epilepsies (Jarecki et al., 2010; Patel et al.,
2016; Xiao et al., 2019). Although ours is the first study to
investigate the impact of SCN2A mutations on resurgent
currents, recordings from DRG neurons demonstrated
that Nav1.2 channels can produce resurgent currents in a
neuronal background (Rush et al., 2005).
The primary effect of the SCN2A R1882Q mutation is
impairment of inactivation, which contributes to both in-
creased persistent and resurgent currents (Grieco and
Raman, 2004; Theile et al., 2011). It has been shown that
the C-terminal domain of Nav1.2 (Mantegazza et al., 2001;
Lee and Goldin, 2008; Nguyen and Goldin, 2010), as well
as Nav1.3 (Nguyen and Goldin, 2010), Nav1.5 (Cormier
et al., 2002; Glaaser et al., 2006), Nav1.6 (Lee and Goldin,
2008; Wagnon et al., 2016), and Nav1.8 (1.5 and 1.8; Choi
et al., 2004; Motoike et al., 2004), is involved in modulat-
ing fast inactivation. In a recent study using ND7/23 cells,
it was shown that the R1872Q mutation in mouse Nav1.6,
which is homologous to the hNav1.2 R1882Q mutation,
slows inactivation (as evidenced by increased inactivation
time constants), hyperpolarizes the voltage dependence
of activation, and depolarizes the voltage dependence of
inactivation, compared to WT (Wagnon et al., 2016). Since
Nav1.2 and Nav1.6 share a high degree of homology in
structure and function (amino acid sequences have 75%
identity, 85% similarity) homologous mutations in the two
isoforms are predicted to have similar functional results.
Our results demonstrate that, like the Nav1.6 R1872Q
mutation, the R1882Q mutation increased inactivation
time constants, indicating a slowing of fast inactivation,
and depolarized the voltage dependence of inactivation.
In our experiments, the R1882Q mutation also increased
persistent currents at physiologically-relevant membrane
potentials (amplitude increased significantly from –50 to
–20 mV, % of transient current increased significantly
from –45 to –25 mV). This effect was seen when R1872 in
Nav1.6 was mutated to leucine, but not when it was
mutated to glutamine or tryptophan. Additionally, the
hNav1.2 R1882Q mutation enhanced resurgent currents,
which were not investigated in the study of the mouse
Nav1.6 R1872Q mutation. There is substantial evidence
suggesting that the C-terminal domain of voltage-gated
sodium channels can modulate fast inactivation and per-
sistent currents by interacting with the Domain III/IV linker
that contains the inactivation particle (Mantegazza et al.,
2001; Motoike et al., 2004; Lee and Goldin, 2008; Nguyen
and Goldin, 2010; Wagnon et al., 2016; Clairfeuille et al.,
2019). The neutralizing R1882Q mutation may directly or
indirectly alter this interaction, thus impairing inactivation
and enhancing persistent currents.
R853Q mutation effects on hNav1.2 function and
predicted effects on neuronal excitability
The recent study of SCN2A mutations expressed in
CHO cells reported that the R853Q mutation in human
Nav1.2 decreases peak transient current density and pro-
duces a hyperpolarizing shift in the voltage dependence
of inactivation (Berecki et al., 2018); these observations
were corroborated in our present study using HEK cells.
Our data also suggested that this mutation reduces per-
sistent and resurgent currents. The reductions in Qmax in
oocytes and in current density in HEK cells resulting from
this mutation, compared to the WT channel, suggest that
this mutation reduces the surface expression of the chan-
nel. All of these are loss-of-function effects, which are
predicted to decrease neuronal excitability. Although loss
of Nav1.2 function is common among late-onset SCN2A
epilepsies, the choreoathetosis associated with the
R853Q mutation suggests an underlying neuronal hyper-
excitability. The only proposed effect of this mutation that
represents an anomalous channel function and, thus, ex-
plains how it may cause neuronal hyperexcitability, is the
creation of a gating pore that conducts cationic current.
Typical neuronal resting membrane potential is around
–70 mV, a membrane potential at which the gating pore in
R853Q mutant channels is conducting. The inward cat-
ionic current, although small, may chronically depolarize
the affected neurons, making them hyperexcitable. Mul-
tiple studies have shown that mutations of the highly
conserved voltage-sensing residues in the second do-
main of Nav channels result in gating pore currents
(Sokolov et al., 2005, 2007, 2008, 2010; Struyk and Can-
non, 2007). Patch clamp data and molecular dynamic
simulations have shown that mutation of the second
voltage-sensing arginine residue in the bacterial channel,
which is homologous to hNav1.2 R853, creates a distinct
gating pore that is open in the resting state channel
conformation (Gamal El-Din et al., 2014; Jiang et al.,
2018). In rat Nav1.2, the R853Q mutation, when paired
with the R850Qmutation, produced an inward gating pore
current in Xenopus oocytes, but the R853Q mutation
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alone did not produce an observable gating pore current
that was significantly different from that of the WT rat
channel (Sokolov et al., 2005). This may indicate a species
difference in susceptibility. The R853Q mutation in
hNav1.2 did not produce an observable gating pore cur-
rent in CHO cells (Berecki et al., 2018); however, this is
likely due to the low current amplitude and density of
R853Q channels in CHO cells. We obtained robust ex-
pression of hNav1.2 channels in Xenopus oocytes and
observed substantial gating pore currents with the
hNav1.2 R853Q construct. The gating pore current am-
plitude is linearly correlated with the gating charge (Fig.
9A), and the slope of the linear increase is –118.0 	 8.8
nA/nC (n  11). By comparison, for the gating pore cur-
rent observed with Nav1.4 in hypokalemic periodic paral-
ysis mutants, the slopes range from 50 to 150 nA/nC
(Struyk and Cannon, 2007; Mi et al., 2014). This indicates
that the severity of the gating pore leak induced by R853Q
in hNav1.2 is comparable to those observed with Nav1.4
disease mutations.
Inward gating pore currents resulting from the mutation
of one of the first two arginines in DIIS4 (in hNav1.2, R850
or R853) are predicted to destabilize and even chronically
depolarize the membrane potential of affected neurons.
Gating pore currents may also disrupt intracellular ion
homeostasis, allowing excess sodium ions and possibly
even protons to leak into affected neurons through the
gating pore (Struyk and Cannon, 2007; Sokolov et al.,
2007). Although the generation of gating pore current
adds an aberrant function to the hNav1.2 channel, the
impact of this anomalous current may depend on the cell
background. A depolarizing influence, such as excess
sodium entry into the cell, could increase the activity of
some neurons by bringing the membrane potential closer
to the action potential firing threshold, while paradoxically
decreasing excitability in others if the depolarization of the
membrane potential reduces sodium channel availability
due to the accumulation of inactivated channels. The
other effects of the R853Q mutation confer a moderate
loss of function on hNav1.2, which is predicted to con-
tribute to decreased neuronal excitability. The dynamic
action potential clamp experiments using CHO cells tran-
siently expressing the Nav1.2 channel used a computer
model of a typical cortical neuron axon initial segment
(Berecki et al., 2018), predicting that the R853Q mutation
would decrease action potential firing activity and thus
reduce overall neuronal excitability. However, the dy-
namic clamp model did not consider the possibility that
gating pore currents may be induced by this mutation,
and that these currents could alter neuronal activity di-
rectly, by reducing the action potential threshold, or indi-
rectly, by chronically impacting ion homeostasis and
energy metabolism in neurons. Such alterations could
cause variable and/or chronic changes in neuronal prop-
erties, and these changes may not be readily apparent
using dynamic clamp or traditional electrophysiological
analyses in heterologous expression systems. Moreover,
seizures in patients with R853Q are refractory to AEDs
that block the conventional Na-conducting pore, consis-
tent with a pathomechanism based on the gating pore
current.
Although the mechanism by which the R853Q mutation
causes the observed clinical phenotype is still unclear, it is
clearly a pathogenic mutation. Mutations in the homolo-
gous residue in three other Nav isoforms (Nav1.1, 1.4, and
1.5) have been shown to be associated with disorders of
excitability. In addition to R853Q, ten other neutralizing
mutations of seven different voltage-sensing residues in
Nav1.2 have been implicated in over 30 patients with
epilepsy syndromes. Three mutations in domains I and III
of hNav1.2 have been studied in vitro (R223Q, R1312T,
and R1319Q). Of these three, one (R1312T, in DIII) also
exhibits a loss-of-function hyperpolarizing shift in fast
inactivation, compared to WT, but R1312T also exhibited
multiple gain-of-function effects that were not seen in our
experiments with the R853Q mutant (Lossin et al., 2012).
The other two (R223Q, R1319Q) were shown to have the
opposite effect, exhibiting a depolarizing shift in the volt-
age dependence of fast inactivation (Scalmani et al.,
2006; Misra et al., 2008). The R1319Q mutation, like
R853Q, has been shown to reduce the current density of
Nav1.2; and the R1319Q mutation was also shown to
reduce the surface expression of the channel (Misra et al.,
2008). Clinically, the R853Q phenotype most resembles
that of R1312T, causing severe seizures that are often
refractory to antiepileptic medications, having a late onset
(typically more than six months), and being accompanied
by severe intellectual disability (Shi et al., 2009; Epi4k
Consortium, 2013; Nakamura et al., 2013; Samanta and
Ramakrishnaiah, 2015; Kobayashi et al., 2016; Li et al.,
2016; Wolff et al., 2017).
Only one other voltage-sensing residue in Domain II of
Nav1.2, R856, has been reported to have mutations im-
plicated in epilepsy (Howell et al., 2015; Moller et al.,
2016; Wolff et al., 2017). The R856L mutation has been
identified in one patient who was diagnosed with epilepsy
of infancy with migrating focal seizures (Howell et al.,
2015), and the R856Q mutation was identified in two
patients diagnosed with Ohtahara syndrome (Moller et al.,
2016; Wolff et al., 2017). Neither mutation has been stud-
ied in the laboratory, as of yet. Seizure onset was reported
to be early (1–2 d) in two of the cases, representing both
mutations (Howell et al., 2015; Wolff et al., 2017). At least
one child with the R856Q mutation was refractory to
antiepileptic medicines and died at the age of three
months (Moller et al., 2016; Wolff et al., 2017). Since
R853Q and R856Q are mutations of adjacent voltage-
sensing residues in the functional Nav1.2 protein, the
proximity of these two residues and the severe, refractory
epileptic phenotypes caused by both suggests that these
mutations may have similar effects on the structure, and
thus also the function of the channel. We predict that
several, if not all, of these other S4 mutations in hNav1.2
may also induce gating pore currents.
Applications
The primary goal of this study was to characterize the
functional effects of two missense mutations on the
hNav1.2 channel, to develop a better understanding of
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the mechanisms by which ion channel mutations lead to
seizure disorders. The various profiles of biophysical
functional changes caused by the epileptogenic SCN2A
mutations that have been studied in vitro suggests that
distinct missense mutations in hNav1.2 have different
mechanisms of seizure generation. For example, R853Q
and R1882Q both lead to severe epilepsy, although with
distinct clinical phenotypes (Carvill et al., 2013; Epi4k
Consortium, 2013; Nakamura et al., 2013; Howell et al.,
2015; Samanta and Ramakrishnaiah, 2015; Kobayashi
et al., 2016; Li et al., 2016; Trump et al., 2016; Wolff et al.,
2017); and, in this study, these mutations have opposite
effects on hNav1.2 persistent current, resurgent current,
and voltage dependence of inactivation. Given that dis-
tinct missense mutations in the same ion channel gener-
ate seizures by unique molecular mechanisms, individual
mutations may require targeted pharmacotherapeutic
strategies to normalize the channel activity and prevent
seizure generation (epileptogenesis). For example, epilep-
tic patients with a mutation that increases persistent cur-
rent as the primary pathologic effect (e.g., A263V; Parrini
et al., 2017) would benefit from a pharmacological com-
pound that selectively inhibits persistent current; while the
same compound would likely be ineffective in patients
with mutations generating seizures through a loss of
channel expression (e.g., R102X; Kamiya et al., 2004). An
ideal pharmacotherapeutic strategy for any epileptic pa-
tient with a pathogenic SCN2A mutation may involve
selectively targeting the specific pathologic biophysical
effects of each mutation, which seem to often include the
enhancement of aberrant currents such as persistent,
resurgent, and gating pore currents. Such a strategy
would maintain or restore healthy channel conductance
and gating, as is seen in WT hNav1.2 channels, so as not
to produce excessive sedation or other adverse effects in
patients. Cannabidiol (CBD) has been demonstrated to
preferentially inhibit resurgent current over transient cur-
rent in hNav1.6 channels expressed in HEK cells, while
also blocking the enhancement of persistent current by an
epileptogenic hNav1.6 mutation (Patel et al., 2016). Al-
though the primary mechanism of antiepileptic action of
CBD is unclear, it is known to antagonize voltage-gated
sodium, potassium, and calcium channels; and it has
shown some promise as an antiepileptic compound in
both preclinical and clinical studies (Jones et al., 2010; Hill
et al., 2014; Mao et al., 2015; Devinsky et al., 2016, 2017;
Patel et al., 2016; Ghovanloo et al., 2018). In June of 2018,
a CBD formulation called Epidiolex (a Schedule I drug
produced by GW Pharmaceuticals; Greenwich Biosci-
ences, Inc., 2018) became the first form of CBD to gain
FDA approval, for the treatment of refractory Dravet syn-
drome and Lennox–Gestaut syndrome (U.S. Food and
Drug Administration, 2018; Drugs.com, 2019; Greenwich
Biosciences, Inc., 2018). We predict that many of the over
two dozen S4 charge neutralizing mutations in Nav1.1,
Nav1.2, and Nav1.6 that have been identified in patients
with epilepsy also induce gating pore currents that con-
tribute to the disease phenotype. Gating pore currents are
unlikely to be targeted by standard clinical therapies and,
thus, novel approaches may be needed to ameliorate the
impact of the gating pore currents produced by some
neuronal sodium channel disease mutations.
Ultimately, we expect that this research will contribute
to a knowledge base and resources that will lead to more
effective treatments for patients with epileptogenic
SCN2A mutations. The next step in that process will be
screening currently available antiepileptic drugs and
novel, putatively antiepileptic compounds in cells ex-
pressing mutant hNav1.2 channels, with the aim of dis-
covering the compound that best normalizes the channel
activity (to resemble that of WT) for each mutation. The
therapeutic value of such compounds could be confirmed
in neurons expressing the mutant channels, and the cor-
relation of patient-reported efficacy of currently-available
antiepileptic drugs with the effects of the same drugs on
mutant channels in vitro could be studied. If the correla-
tion is strong, then the in vitro studies could provide
suggestions of compounds that will likely be efficacious in
patients with particular epileptogenic mutations.
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